Intra-Cellular Therapies makes Caplyta, a once-daily pill for adults with schizophrenia and bipolar-related depression ...
Johnson & Johnson has underperformed its large-cap healthcare peers and the S&P 500, with an -8% decline over the past year.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback